Anti-CD37 radioimmunotherapy with ¹⁷⁷Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.

Autor: Malenge, Marion M.^1,2,3 (AUTHOR), Maaland, Astri Fjelde^1,2 (AUTHOR), Repetto-Llamazares, Ada¹ (AUTHOR) arepetto@nordicnanovector.com, Middleton, Brian⁴ (AUTHOR), Nijland, Marcel⁵ (AUTHOR), Visser, Lydia⁵ (AUTHOR), Patzke, Sebastian^1,3 (AUTHOR), Heyerdahl, Helen¹ (AUTHOR), Kolstad, Arne⁶ (AUTHOR), Stokke, Trond³ (AUTHOR), Ree, Anne Hansen^2,7 (AUTHOR), Dahle, Jostein¹ (AUTHOR)

Publikováno v: PLoS ONE. 4/29/2022, Vol. 17 Issue 4, p1-22. 22p.

Combination of ¹⁷⁷Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma.

Autor: Repetto‐Llamazares, Ada H. V.¹ arepetto@nordicnanovector.com, Malenge, Marion M.^1,2,3, O'Shea, Adam¹, Eiríksdóttir, Bergthóra⁴, Stokke, Trond², Larsen, Roy H.⁵, Dahle, Jostein¹

Publikováno v: European Journal of Haematology. Oct2018, Vol. 101 Issue 4, p522-531. 10p.

¹⁷⁷Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.

Autor: Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H. V.

Publikováno v: Journal of Nuclear Medicine; Dec2020, Vol. 61 Issue 12, p1-36, 36p

¹⁷⁷ Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.

Autor: Malenge MM; Nordic Nanovector ASA, Oslo, Norway.; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Patzke S; Nordic Nanovector ASA, Oslo, Norway.; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Ree AH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway; and., Stokke T; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Ceuppens P; Inferstats Consulting Ltd., Cheshire, United Kingdom., Middleton B; Inferstats Consulting Ltd., Cheshire, United Kingdom., Dahle J; Nordic Nanovector ASA, Oslo, Norway jdahle@nordicnanovector.com., Repetto-Llamazares AHV; Nordic Nanovector ASA, Oslo, Norway.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 Oct; Vol. 61 (10), pp. 1468-1475. Date of Electronic Publication: 2020 Apr 03.